Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
Lipoprotein(a), the low-density lipoprotein (LDL)-like particle that is currently the focus of so much enthusiastic research, is significantly more atherogenic than LDL cholesterol, according to a ...
Elevated lipoprotein(a) increases the risk of major adverse cardiovascular events in patients with and without preexisting atherosclerotic cardiovascular disease (ASCVD), a new study shows. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback